General Federal Contracts — July 20, 2026

Leidos Biomedical Research secured a $4.81 billion contract from HHS, representing 93% of total obligation and the only bullish signal in the period. The high materiality (8/10) suggests significant revenue potential, though the defense classification and missing pricing details warrant caution.

Cardinal Intellectual Property Inc. won a $191.9 million firm-fixed-price USPTO contract spanning 13 years (2012-2025), providing predictable annual revenue of ~$14.8 million. However, $0 outlayed suggests the contract may not yet be active, delaying revenue recognition.

OptumServe Health Services' $190 million VA disability exam contract is 92.4% outlayed with no option periods remaining, indicating near-complete execution. The firm faces recompetition risk for future VA Region 2 disability exam contracts.

Cardinal Intellectual Property's $192M USPTO contract has $0 outlayed despite a 2012 start date, suggesting the contract may be stalled or not yet active, delaying expected revenue.

Leidos Biomedical Research's $4.81B contract represents 93% of total digest value, creating extreme single-contract concentration risk for Leidos if the contract faces delays, protests, or budget cuts.

OptumServe's $190M VA contract is nearly complete with no options, exposing UnitedHealth Group to recompetition risk for future VA disability examination contracts in the Southeast region.

Leidos Biomedical Research's $4.81B HHS contract signals strong demand for biomedical research support services, potentially opening follow-on awards or task orders for Leidos in the health and life sciences sector.

Cardinal Intellectual Property's $192M USPTO contract, once activated, provides a stable ~$14.8M annual revenue stream through 2025, offering long-term visibility for the company.

Two of three contracts (Leidos Biomedical Research and OptumServe) totaling $5.0 billion are tied to health-related services (HHS and VA), indicating strong civilian agency demand for medical research and disability examination services.

Cardinal Intellectual Property's $192M USPTO contract is funded by patent fees rather than annual appropriations, reducing vulnerability to budget uncertainty and offering a unique revenue stability profile.

{"entity"=>"Leidos Holdings", "reason"=>"Leidos Biomedical Research's $4.81B HHS contract is the largest award in the digest and carries execution and budget risks.", "trigger"=>"HHS budget appropriations, CR resolution, or any modification to the Leidos contract"}

{"entity"=>"Cardinal Intellectual Property Inc.", "reason"=>"The $192M USPTO contract has zero outlays, raising questions about activation and revenue recognition.", "trigger"=>"First outlay reported on USASpending.gov or contract modification announcement"}

{"entity"=>"UnitedHealth Group", "reason"=>"OptumServe's $190M VA contract is nearly complete, exposing the company to recompetition risk.", "trigger"=>"New VA solicitation for Region 2 disability examination services"}